<DOC>
	<DOCNO>NCT00622609</DOCNO>
	<brief_summary>GSK249320 monoclonal antibody direct myelin associate glycoprotein ( MAG ) , protein inhibits axonal regeneration . GSK249320 act MAG antagonist , activity hypothesise enhance recovery neuronal degeneration follow acute axonal injury , occur spinal cord injury stroke .</brief_summary>
	<brief_title>Anti-MAG First Administration Human</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<criteria>Healthy adult men woman nonchild bear potential ( i.e . postmenopausal surgically sterile e.g . hysterectomy bilateral oophorectomy ) . If necessary , postmenopausal status confirm serum FSH oestradiol concentration screen . Surgical sterility define female document hysterectomy bilateral oophorectomy . Between 18 60 year age inclusive . Body weight &gt; / 60 kg BMI within range 1929.9 kg/m2 inclusive . Healthy judge responsible physician clinically significant abnormality identify medical laboratory evaluation . A subject clinical abnormality laboratory parameter outside reference range age group may include Investigator considers find introduce additional risk factor interfere study procedure . A 12lead ECG prestudy screen opinion Investigator his/her designee abnormality compromise safety study . Normal clinical neurological exam , normal QST result , normal pattern conduction latency medial , ulnar , sural , tibial peroneal nerve screen . Signed date write informed consent prior admission study . The subject able understand comply protocol requirement , instruction protocolstated restriction . Positive drug/ alcohol screen screen baseline . Positive prestudy HIV , Hepatitis B surface antigen positive Hepatitis C antibody result screen . History acute neuronal injury ( central peripheral ) within previous 12 month , peripheral neuropathy neuritis , neurodegenerative disorder neurological disease , include condition know hypothesise associate disruption bloodbrain barrier ( BBB ) . Considered high risk develop stroke include history carotid artery disease surgery , transient ischaemic attack , reversible ischaemic neurological deficit abnormality brain vessel , include limited berry aneurysms arteriovenous malformation . History regular alcohol consumption average &gt; 7 drinks/week woman &gt; 14 drinks/week men . One drink equivalent ( 12 g alcohol ) = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) 80 proof distil spirit ) within 6 month screen . Subjects smoke 10 cigarette per day . Subjects smoke &lt; 10 cigarette per day may admit study ask refrain smoking least 24 hour plan day admission unit . They NOT allow smoke stay unit . The subject unable abstain strenuous physical activity 72 h prior clinic visit safety lab test conduct . The subject participate clinical trial receive investigational product within following time period prior dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Where participation study would result donation blood excess 500 mL within 56 day period . Previous exposure humanise antibody therapy reason . Unwillingness male subject abstain sexual intercourse pregnant lactate woman time first dose study medication five half life follow administration dose study medication . This may increase depend PK analysis study . Unwillingness male subject use condom/spermicide addition female partner use another form contraception intrauterine device ( IUD ) , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation woman could become pregnant time first dose study medication five half life follow administration last dose study medication . The duration period contraception must practice may modify study , depend data emerge PK analysis . The mean halflife predict GSK249320 30 day Female subject positive urine/serum pregnancy test result screen prior first dose Status `` vulnerable '' subject , define US Food Drug Administration ( FDA ) Code Federal Regulations ; 45 CFR , Section 46 , Subparts B C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>first time human ,</keyword>
	<keyword>MAG</keyword>
	<keyword>monoclonal antibody ,</keyword>
	<keyword>healthy subject ,</keyword>
	<keyword>GSK249320 ,</keyword>
</DOC>